AusBiotech has launched the latest edition of the Australasian Biotechnology Journal ahead of AusMedtech 2026, bringing together perspectives from across Australia’s life sciences ecosystem.
The Journal showcases insights from leaders spanning biotechnology, medical technology, digital health, investment, research, policy, and commercialisation, reflecting the breadth and strength of Australia’s innovation pipeline.
Released ahead of AusMedtech, Australia’s flagship medtech conference, the publication highlights key sector priorities, emerging opportunities, and the importance of collaboration across industry, research, government, and healthcare.
Rebekah Cassidy, CEO, AusBiotech, said, “The pace of innovation across Australia’s life sciences sector continues to accelerate, driven not only by breakthrough discoveries, but also by the increasingly powerful convergence of disciplines that were once considered distinct.
“Today, the boundaries between biotechnology, medical technology, and digital and connected health are rapidly dissolving, creating new opportunities to improve patient outcomes, strengthen health systems, and build globally competitive companies.”
Topics explored throughout this edition include the future of medtech in Australia, the growing momentum behind women’s health innovation, an interview with Dr Josh Makower on innovation with intent, and Australia’s evolving digital health landscape.
This edition includes updates from AusBiotech’s leadership team on the state of the sector, key industry priorities, and AusBiotech’s progress towards its mission of supporting and advancing Australia’s life sciences ecosystem.
AusBiotech thanked all contributors who shared their expertise and helped make this edition possible, including:
- Bronwyn Le Grice, Founder, CEO and Managing Director, ANDHealth;
- Tara Croft, Chief Executive Officer, Baymatob;
- Dig Howitt, Chief Executive Officer and President, Cochlear;
- John Skinner, General Manager and Director, Cook Medical Australia;
- Dr Josh Makower, Yock Family Professor of Medicine and Bioengineering, Stanford University, and Director and Co-founder, Stanford Mussallem Center for Biodesign;
- Dr Nicholas Pachuda, General Partner, Neovate Capital; Chief Operating Officer, Peptilogics; and Co-founding Partner, Precision Life Science Partners;
- Naomi Omundson, Partner, McCullough Robertson; Reece Walker, Partner, McCullough Robertson; and Melissa Miller, Partner, McCullough Robertson;
- Paul Anderson, Chief Executive Officer, Orthocell;
- Stuart Elliott, Chief Executive Officer and Co-founder, Planet Innovation;
- Therapeutic Goods Administration;
- David Peacock, Chief Executive Officer, Vaxxas; and,
- The Government of Western Australia.
Ms Cassidy added, “Australia has long been recognised for scientific excellence and world-class research. As more Australian health innovators scale and partner globally, AusBiotech is proud to enter its 40th year standing with our sector and enabling growing intersections between biotech, medtech and digital/connected health.
“At AusBiotech, we look forward to continuing to support our vibrant and evolving ecosystem as it works to translate innovation and unlock impact for patients and healthcare systems everywhere.”
The launch comes as the sector continues to advocate for stronger national coordination and investment to support growth across Australia’s biotechnology and medtech industries.